

Auro Viswabandya

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2246141/auro-viswabandya-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

50
papers

257
citations

10
h-index

15
g-index

59
ext. papers

410
ext. citations

3
avg, IF

3.09
L-index

#	Paper	IF	Citations
50	Anti-thymocyte globulin and post-transplant cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts. <i>European Journal of Haematology</i> , 2022 , 108, 61-72	3.8	1
49	Allogeneic Hematopoietic Stem Cell Transplantation in Therapy Related Acute Leukemia. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2021 , 37, 521-527	0.7	0
48	Moderate-severe grade of chronic graft versus host disease and younger age (less than 45 years old) are risk factors for avascular necrosis in adult patients undergoing allogeneic hematopoietic cell transplantation. <i>Annals of Hematology</i> , 2021 , 100, 1311-1319	3	
47	Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1908-1918	4.4	2
46	Experience Using Anti-Thymocyte Globulin With Post-Transplantation Cyclophosphamide for Graft-Versus-Host Disease Prophylaxis in Peripheral Blood Haploidentical Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 428.e1-428.e9		1
45	Efficacy and cost analysis of eltrombopag in thrombocytopenia and poor graft function post allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021 , 56, 2471-2476	4.4	2
44	Comparison of the Prognostic Ability of the HCT-CI, the Modified EBMT, and the EBMT-ADT Pre-transplant Risk Scores for Acute Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, e559-e568	2	1
43	Effect of pre-transplant JAK1/2 inhibitors and CD34 dose on transplant outcomes in myelofibrosis. <i>European Journal of Haematology</i> , 2021 , 107, 517-528	3.8	0
42	Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Acta Haematologica</i> , 2021 , 144, 66-73	2.7	2
41	Pilot prospective study of Frailty and Functionality in routine clinical assessment in allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021 , 56, 60-69	4.4	10
40	Effect of donor age and kinship on outcomes in haplo-identical stem cell transplantation may be modulated by GVHD prophylaxis strategies. <i>Bone Marrow Transplantation</i> , 2021 , 56, 689-691	4.4	1
39	Clinical prevalence and outcome of cardiovascular events in the first 100 days postallogeneic hematopoietic stem cell transplant. <i>European Journal of Haematology</i> , 2021 , 106, 32-39	3.8	6
38	Prolactin, a potential biomarker for chronic GVHD activity. <i>European Journal of Haematology</i> , 2021 , 106, 158-164	3.8	1
37	Subcutaneous immunoglobulin in allogeneic hematopoietic cell transplant patients: A prospective study of feasibility, safety, and healthcare resource use. <i>Hematology/Oncology and Stem Cell Therapy</i> , 2021 , 14, 302-310	2.7	0
36	Association of Factors Influencing Selection of Upfront Hematopoietic Cell Transplantation versus Nontransplantation Therapies in Myelofibrosis. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 600.e1-600.e8		2
35	Lower dose of ATG combined with post-transplant cyclophosphamide for HLA matched RIC alloHCT is associated with effective control of GVHD and less viral infections. <i>Leukemia and Lymphoma</i> , 2021 , 1-11	1.9	0
34	Refined hepatic grading system in chronic graft-versus-host disease improves prognostic risk stratification of long-term outcomes. <i>European Journal of Haematology</i> , 2021 , 106, 508-519	3.8	

33	Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation. <i>Annals of Hematology</i> , 2020 , 99, 1377-1387	3	3
32	Less Is More: Superior Graft-versus-Host Disease-Free/Relapse-Free Survival with Reduced-Intensity Conditioning and Dual T Cell Depletion in Acute Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1511-1519	4.7	1
31	Outcomes of therapy-related acute lymphoblastic leukemia in adults after allogeneic stem cell transplantation. <i>European Journal of Haematology</i> , 2020 , 105, 24-29	3.8	1
30	Dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning allo-HSCT results in very low rates of GVHD. <i>Bone Marrow Transplantation</i> , 2020 , 55, 1773-1783	4.4	14
29	Haploidentical Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with Myelofibrosis: A Multi-Institutional Experience. <i>Blood</i> , 2020 , 136, 33-34	2.2	3
28	Allogeneic Hematopoietic Stem Cell Transplant Versus Gene Therapy in Sickle Cell Disease: Updated Results from a Systematic Review. <i>Blood</i> , 2020 , 136, 11-12	2.2	
27	Improving medication reconciliation in ambulatory cancer care.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 224-224	2.2	
26	Impact of CD34+ cell dose on reduced intensity conditioning regimen haploidentical hematopoietic stem cell transplantation. <i>European Journal of Haematology</i> , 2020 , 104, 36-45	3.8	2
25	High incidence but low mortality of EBV-reactivation and PTLD after alloHCT using ATG and PTCy for GVHD prophylaxis. <i>Leukemia and Lymphoma</i> , 2020 , 61, 3198-3208	1.9	3
24	My jamais vu in post allogeneic hematopoietic cell transplant: a review on secondary hemophagocytosis in adults. <i>Bone Marrow Transplantation</i> , 2020 , 55, 867-872	4.4	4
23	Reduced intensity allogeneic stem cell transplant with anti-thymocyte globulin and post-transplant cyclophosphamide in acute myeloid leukemia. <i>European Journal of Haematology</i> , 2019 , 103, 510-518	3.8	10
22	Low rates of acute and chronic GVHD with ATG and PTCy in matched and mismatched unrelated donor peripheral blood stem cell transplants. <i>European Journal of Haematology</i> , 2019 , 102, 486-493	3.8	18
21	Epstein-Barr virus associated post-transplant lymphoproliferative disorder mimicking acute graft versus host disease. <i>European Journal of Haematology</i> , 2019 , 103, 519-522	3.8	1
20	Impressive Graft-versus-Host Disease-Free, Relapse-Free Survival in Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-Intensity Conditioning and a Combination of Antithymocyte Globulin and Post-Transplantation Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, e387-e388	4.7	2
19	Dual T Cell Depletion with Anti-Thymocyte Globulin and Post-Transplant Cyclophosphamide Results in Low Rates of Cytokine Release Syndrome in Peripheral Blood Haplo-Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, e387-e388	4.7	2
18	Reduced-intensity conditioning allogeneic transplant with dual T-cell depletion in myelofibrosis. <i>European Journal of Haematology</i> , 2019 , 103, 597-606	3.8	6
17	Safety and Efficacy of Haploidentical Peripheral Blood Stem Cell Transplantation for Myeloid Malignancies Using Post-transplantation Cyclophosphamide and Anti-thymocyte Globulin as Graft-Host Disease Prophylaxis. <i>Clinical Hematology International</i> , 2019 , 1, 105-113	1.8	14
16	Largest Single Center Experience Using Dual T-Cell Depletion with ATG and Ptcy for Gvhd Prophylaxis in Peripheral Blood RIC Allo-HSCT. <i>Blood</i> , 2019 , 134, 3344-3344	2.2	

15	The 17-Gene Leukemic Stemess Score Can Predict Treatment Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia. <i>Blood</i> , 2019 , 134, 3299-3299	2.2	
14	Reduced Intensity Conditioning and Dual T-Cell Modulation Improves Gvhd Free, Relapse Free Survival in AML Patients Compared with Myeloablative Conditioning. <i>Blood</i> , 2019 , 134, 4590-4590	2.2	
13	No Impact of Donor's Age-Related Clonal Hematopoiesis (ARCH) Observed on Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: Result from Bar-Coded Error Corrected Sequencing in 33 Gene Mutations on 372 Pairs of Donor and Recipient. <i>Blood</i> , 2019 , 134, 4514-4514	2.2	
12	Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 256-264	4.7	33
11	Efficacy of Cidofovir in Treatment of BK Virus-Induced Hemorrhagic Cystitis in Allogeneic Hematopoietic Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1901-1905	4.7	21
10	Therapeutic efficacy of azathioprine in addition to prednisone-based regimens as first-line chronic graft-versus-host disease treatment. <i>Bone Marrow Transplantation</i> , 2018 , 53, 334-338	4.4	0
9	Reduction of severe acute graft-versus-host disease using a combination of pre transplant anti-thymocyte globulin and post-transplant cyclophosphamide in matched unrelated donor transplantation. <i>Bone Marrow Transplantation</i> , 2018 , 53, 361-365	4.4	16
8	Characteristics, treatment and outcomes of nontuberculous mycobacterial pulmonary disease after allogeneic haematopoietic stem cell transplant. <i>European Respiratory Journal</i> , 2018 , 51,	13.6	8
7	Incidence and Risk Factors for Nontuberculous Mycobacterial Infection after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 366-372	4.7	20
6	Fludarabine and busulfan plus low-dose TBI as reduced intensity conditioning in older patients undergoing allogeneic hematopoietic cell transplant for myeloid malignancies. <i>Annals of Hematology</i> , 2018 , 97, 1975-1985	3	3
5	Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2259-2264	4.7	36
4	Progressive multifocal leukoencephalopathy due to John Cunningham (JC) virus following allogeneic haematopoietic cell transplantation. <i>Antiviral Therapy</i> , 2017 , 22, 721-725	1.6	1
3	Distinctive clinical characteristics and favorable outcomes in patients with large granular lymphocytosis after allo-HCT: 12-year follow-up data. <i>European Journal of Haematology</i> , 2017 , 99, 160-168	3.8	3
2	Post Transplant Cyclophosphamide (PTCy) with Anti-Thymocyte Globulin (ATG) Effectively Reduces the Severe (Grade III-IV) Acute Graft-Versus-Host Disease (GVHD) When Compared to ATG Alone in Matched Unrelated Donor (MUD) Allogeneic Hematopoietic Cell Transplants. <i>Blood</i> , 2016 , 128, 3430-3430	2.2	1
1	Comparison of Pharmacokinetics and Pharmacodynamics of Two Anti-CD20 Monoclonal Antibodies (Candidate Biosimilar DRL-Rituximab and Innovator Reference Product Rituximab (Mabthera®)) in a Randomised, Multi-Centre, Double-Blind, Parallel Group Study of CHOP with Rituximab Chemotherapy in Patients with CD20-Positive Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016 , 128, 5391-5391	2.2	